Skip to content
WHWKWhitehawk Therapeutics, Inc.

Earnings

When Whitehawk Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

66 quarters. Jun 30, 2010 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 11, before the open

Thu, Mar 11, 2027in 113 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 8 – 31

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$0.00
Revenue, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 −100.0%, Q4 2025 −100.0%
Net income
-$23.25M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$0.00No Q3 2025 on file

Latest results

  1. Q3 2026Nov 9, 2026, before the openThe release+3.0%by the close of Nov 9
    Revenue
    $0.00
    —
    Net income
    -$21.21M
    N/M
    EPS
    -$0.23
    N/M
    Initiated the Phase 1 clinical trial of HWK-206 in the U.S. and received Fast Track designation from the U.S. Food and Drug Administration (FDA).
  2. Q2 2026Aug 6, 2026, during market hoursThe release+14.8%by the close of Aug 6
    Revenue
    $0.00
    —
    Net income
    -$16.64M
    N/M
    EPS
    -$0.20
    N/M
  3. Q1 2026May 7, 2026, before the openThe release4.6%by the close of May 7
    Revenue
    $0.00
    −100.0%
    Net income
    -$22.19M
    N/M
    EPS
    -$0.32
    N/M
  4. Q4 2025Mar 12, 2026, before the openThe release3.0%by the close of Mar 12
    Revenue
    $0.00
    −100.0%
    Net income
    -$23.25M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 9, 2026 · pre-marketNov 9, 202640 d10-Q$0.00—-$0.23+3.0%
Q2 2026Jun 30, 2026Aug 6, 2026 · market hoursAug 6, 202637 d10-Q$0.00—-$0.20+14.8%
Q1 2026Mar 31, 2026May 7, 2026 · pre-marketMay 7, 202637 d10-Q$0.00−100.0%-$0.324.6%
FY 2025
Q4 2025derivedDec 31, 2025Mar 12, 2026 · pre-marketMar 12, 202671 d10-K$0.00−100.0%—3.0%
Q3 2025Sep 30, 2025Nov 6, 2025 · pre-marketNov 6, 202537 d10-Q$0.00−100.0%-$0.266.9%
Q2 2025Jun 30, 2025Aug 7, 2025 · pre-marketAug 7, 202538 d10-Q$0.00−100.0%-$0.765.2%
Q1 2025Mar 31, 2025May 8, 2025 · after-hoursMay 8, 202538 d10-Q$7.15M+33.5%$1.83+4.0%
FY 2024
Q4 2024derivedDec 31, 2024Mar 18, 2025 · after-hoursMar 28, 202587 d10-K$7.24M+14.4%—1.5%
Q3 2024Sep 30, 2024Nov 6, 2024 · pre-marketNov 6, 202437 d10-Q$7.21M+21.0%-$0.46+7.0%
Q2 2024Jun 30, 2024Aug 7, 2024 · pre-marketAug 7, 202438 d10-Q$6.18M−0.4%-$0.54—
Q1 2024Mar 31, 2024May 8, 2024 · pre-marketMay 8, 202438 d10-Q$5.35M−8.8%-$0.68—
Earlier years, FY 2010 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 9, 2026453576
10-QAug 6, 2026337933
10-QMay 7, 2026212075
10-KMar 12, 2026104158
10-QNov 6, 2025268895
10-QAug 7, 2025105081
10-QMay 8, 2025023932
10-KMar 28, 2025015269
10-QNov 6, 2024045698
10-QAug 7, 2024035636

Provenance

ProvenanceData status and checks

Whitehawk Therapeutics, Inc. · CIK 1422142 · Engraved from SEC EDGAR